Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.61, representing a +1.88% change from its previous close.

A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (NASDAQ: VKTX) stock on Friday, which closed the trading session 3% higher. That figure was ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising ...

Weight-management treatments are all the rage lately. According to Morgan Stanley, combined sales of injections that curb appetites and promote weight loss could reach an estimated $105 billion by ...

Viking has found a manufacturing partner, removing a key overhang on the stock Viking Therapeutics Inc.'s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a ...

Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront ...

Could 2024 be a breakout year for Viking Therapeutics (NASDAQ: VKTX)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to ...